A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive haemophilus influenzae type b disease

New England Journal of Medicine

Volumn 323, Issue 20, 1990, Pages 1381-1387

  Eskola, Juhani ^a   Käyhty, Helena ^a   Takala, Aino K ^a   Peltola, Heikki ^a   Rönnberg, Pirjo Riitta ^a   Kela, Eija ^a   Pekkanen, Eeva ^a   McVerry, Patrick H ^b   Mäkelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Connaught Laboratories ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FINLAND; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; VACCINATION;

AGE FACTORS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNIZATION SCHEDULE; INFANT; MALE; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0025223770     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199011153232004     Document Type: Article

References (33)

1. Ward J, Cochi S. Haemophilus influenzae vaccines. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia: W.B. Saunders, 1988:300–32.
2. Peltola H, Käyhty H, Virtanen M, Mäkelä PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310: 1561–6.
3. Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR 1985; 34: 201–5.
4. Harrison LH, Broome CV Hightower AW, et al. A day care—based study of the efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260: 1413–8.
5. Shapiro ED, Murphy TV. Wald ER, Brady CA. The protective efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260: 1419–22.
6. Osterholm MT, Rambeck JH, White KE, et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1988; 260: 1423–8.
7. Black SB, Shinefield HR. Hiatt RA, Fireman BH, Kaiser Permanente Pediatric Vaccine Study Group. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J 1988; 7: 149–56.
8. Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr 1988; 113: 621–31.
9. Eskola J, Käyhty H, Peltola H, et al. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1985; 1: 1184–6.
10. Anderson PW, Pichichero ME, Insel RA, Betts R, Eby R, Smith DH. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol 1986; 137: 1181–6.
11. Einhorn MS, Weinberg GA, Anderson EL, Granoff PD, Granoff DM. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986; 2: 299–302.
12. Käyhty H, Peltola H, Eskola J, et al. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6 and 14 months of age. Pediatrics 1989; 84: 995–9.
13. Käyhty H, Eskola J, Peltola H, Stout MG, Samuelson JS, Gordon LK. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis 1987; 155: 100–6.
14. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317: 717–22.
15. Ward JI, Brenneman G, Letson G, Heyward W, Alaska Vaccine Efficacy Trial Study Group. Limited protective efficacy of an H. influenzae type b conjugate vaccine (PRP-D) in native Alaskan infants immunized at 2, 4 and 6 months of age. In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, October 23–26, 1988. Washington, D.C.: American Society for Microbiology, 1988. abstract.
16. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152: 361–76.
17. Gordon LK. Characterization of a hapten-carrier conjugate vaccine: Haemophilus influenzae — diphtheria conjugate vaccine. In: Chanock RM, Lerner RA. eds. Modern approaches to vaccines: molecular and chemical basis of virus virulence and immunogenicity. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1984:393–6.
18. Takala AK, Eskola J. Peltola H, Mäkelä PH. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 1989; 8: 297–302.
19. Takala AK, van Alphen L, Musser JM, et al. Bacteriologic epidemiology of Hemophilus influenzae type b strains causing invasive infections in Finland. J Infect Dis 1989; 160: 237–42.
20. Ward JI, Greenberg DP, Anderson PW, et al. Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay. J Clin Microbiol 1988; 26: 72–8.
21. Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 1980; 142: 861–8.
22. Käyhty H, Peltola H, Eskola J. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children. Pediatr Infect Dis J 1988; 7: 574–7.
23. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev 1988; 10: 212–41.
24. Armitage P. Statistical methods in medical research. Oxford. England: Blackwell Scientific, 1971:139.
25. Käyhty H, Jousimies-Somer H, Peltola H, Mäkelä PH. Antibody response to capsular polysaccharides of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J Infect Dis 1981; 143: 32–41.
26. Käyhty H. Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100.
27. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149: 1034–5.
28. Ward JI, Lum MK, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis 1986; 153: 17–26.
29. Takala AK, Eskola J, Palmgren J, et al. Risk factors of invasive Haemophilus influenzae type b disease among children in Finland. J Pediatr 1989; 115: 694–701.
30. Ward JI, Brenneman G, Lepow M, Lum M. Burkhart K, Chiu CY. Haemophilus influenzae type b anticapsular antibody responses to PRP-pertussis and PRP-D vaccines in Alaska native infants. J Infect Dis 1988; 158: 719–23.
31. Takala AK. Epidemiology and risk factors of invasive Haemophilus influenzae type b (Hib) disease among children in Finland. Helsinki, Finland: National Public Health Institute, 1989. (Publication no. 82.)
32. Ward JI, Margolis HS, Lum MK, Fraser DW, Bender TR, Anderson P. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1981; 1: 1281–5.
33. Mäkelä PH, Eskola J, Peltola H, Takala AK, Käyhty H. Clinical experience with Haemophilus influenzae type b conjugate vaccines. Pediatrics 1990; 85: Suppl: 651–3.